Yifu Tablets

This product is an anti-tuberculosis drug, a compound preparation of rifampicin and isoniazid. Rifampicin has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Isoniazid has a highly selective bactericidal effect on all types of Mycobacterium tuberculosis, with a strong effect on Mycobacterium tuberculosis in the growth and reproduction period, and a weaker and slower effect on the dormant period. The combination of the two can enhance the antibacterial activity and reduce the production of drug-resistant strains. Rifampicin firmly binds to the beta subunit of the DNA-dependent RNA polymerase, inhibits the synthesis of bacterial RNA, prevents the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein. The mechanism of action of isoniazid may be to inhibit the synthesis of mycolic acid in sensitive bacteria and cause the cell wall to rupture.

This product is a compound preparation, the active ingredients of which are rifampicin and isoniazid.

It is suitable for the 4-month maintenance treatment of patients with tuberculosis who are first-time patients and non-multi-drug-resistant tuberculosis.

Common dosage for adults: Oral administration. For patients weighing less than 50kg, take 0.45g of rifampicin and 0.3g of isoniazid orally once a day. For patients weighing more than 50kg, take 0.6g of rifampicin and 0.3g of isoniazid orally once a day. Take 30 minutes before or 2 hours after meals. The general course of treatment is 4 months.

1. Digestive tract reactions are the most common. After oral administration of this product, gastrointestinal reactions such as loss of appetite, nausea, vomiting, upper abdominal discomfort, and diarrhea may occur. 2. Hepatotoxicity is the main adverse reaction of this product. In the first few weeks of treatment, a small number of patients may experience elevated serum aminotransferase, hepatomegaly, and jaundice. Most of them are transient asymptomatic elevations of serum aminotransferase, which can recover on their own during the course of treatment. It is more likely to occur in the elderly, alcoholics, malnourished people, people with pre-existing liver disease or other factors that cause abnormal liver function. Adverse reactions manifest as poor appetite, abnormal fatigue or weakness, nausea or vomiting (prodromal symptoms of hepatotoxicity) and dark urine, yellowing of eyes or skin (hepatotoxicity). 3. Allergic reactions include fever, polymorphic rash, lymphadenopathy, vasculitis, purpura, asthma, anaphylactic shock, etc. After high-dose intermittent therapy, "flu-like syndrome" may occasionally occur, manifested as chills, chills, fever, discomfort, dyspnea, dizziness, drowsiness, and muscle pain. The frequency of occurrence is significantly related to the dose size and intermittent time. Acute hemolysis or renal failure may occur occasionally, and its mechanism is currently believed to be an allergic reaction. 4. Nervous system toxicity: Peripheral neuritis is more common in slow acetylation and has a significant relationship with the dose. Many patients show unsteady gait, numbness, tingling, burning sensation or pain in the hands and feet. This reaction is more likely to occur in lead poisoning, arteriosclerosis, hyperthyroidism, diabetes, alcoholism, malnutrition and pregnant women. Taking 10-50 mg of vitamin B6 daily can prevent or relieve symptoms. Other adverse reactions such as excitement, euphoria, insomnia, loss of autonomy, toxic encephalopathy or toxic psychosis are rare, and severe toxic reactions such as optic neuritis and atrophy are occasionally reported. 5. The blood system may have granulocytopenia, eosinophilia, thrombocytopenia, methemoglobinemia, etc. 6. Others such as shortened prothrombin time, headache, dizziness, dry mouth, hypertension, vitamin B6 deficiency, hyperglycemia, metabolic acidosis, endocrine dysfunction, etc. are occasionally reported. .

1. Patients who are allergic to isoniazid, rifampicin and rifamycin antibiotics are contraindicated. 2. Patients with severe liver dysfunction, biliary obstruction and pregnant women within 3 months are contraindicated.

1 Drinking alcohol can increase the incidence of hepatotoxicity of this product and increase the metabolism of this product. The dosage needs to be adjusted, and the patient should be closely observed for hepatotoxicity. 2 Para-aminosalicylate can affect the absorption of this product, resulting in a decrease in the blood concentration of rifampicin; if combined use is necessary, the interval between taking the two should be at least 6 hours. 3 The combination of this product with ethionamide, pyrazinamide or other anti-tuberculosis drugs can aggravate its adverse reactions. Combination with other hepatotoxic drugs can increase the hepatotoxicity of this product and should be avoided as much as possible. 4 Chlorophenazine can reduce the absorption of rifampicin, delay the peak time and prolong the half-life. 5 Combination with miconazole or ketoconazole can reduce the blood concentrations of the latter two, so this product should not be used in combination with imidazoles. 6. When adrenocortical hormones (glucocorticoids, mineralocorticoids), anticoagulants, aminophylline, theophylline, chloramphenicol, clofibrate, cyclosporine, verapamil (Isopamine), tocainide, propafenone, trimethoprim, coumarin or indandione derivatives, oral hypoglycemic drugs, corticotropin, dapsone, digitalis glycosides, disopyramide, quinidine, etc. are used in combination with this product, rifampicin can induce liver microsomal enzyme activity, which can weaken the efficacy of the above drugs. Therefore, except for digoxin and dapsone, the above drugs need to adjust the dosage before and during the treatment of this product. When this product is used in combination with coumarin or indandione, the prothrombin time should be measured daily or regularly to adjust the dosage accordingly. 7. This product can promote the metabolism of estrogen or reduce its enterohepatic circulation, reduce the effect of oral contraceptives, and lead to irregular menstruation, intermenstrual bleeding and unplanned pregnancy. Therefore, when patients take this product, they should use other contraceptive methods instead. 8 This product can induce liver microsomal enzymes, increase the metabolism of anti-tumor drugs dacarbazine and cyclophosphamide, form alkylated metabolites, and promote the decrease of white blood cells, so the dosage needs to be adjusted. 9 Combination with diazepam (Valium) can increase the elimination of the latter and reduce its blood concentration, so the dosage needs to be adjusted. 10 This product can increase the metabolism of phenytoin in the liver, so the blood concentration of phenytoin should be measured and the dosage should be adjusted when the two are used together. 11 This product can increase the degradation of levothyroxine in the liver, so the dose of levothyroxine should be increased when the two are used together. 12 This product can also increase the metabolism of methadone and mexiletine in the liver, causing methadone withdrawal symptoms and reduced mexiletine blood concentration, so the latter two need to adjust the dose when used together. 13 Probenecid can compete with rifampicin for uptake by liver cells, increase rifampicin blood concentration and produce toxic reactions. However, this effect is unstable, so it is usually not appropriate to add probenecid to increase the blood concentration of this product. 14 Isoniazid is an antagonist of vitamin B6, which can increase the amount of vitamin B6 excreted through the kidneys and easily cause peripheral neuritis. Those who take vitamin B6 at the same time need to increase the dosage as appropriate. 15 This product should not be used in combination with other neurotoxic drugs to avoid increasing neurotoxicity. 16 When used in combination with cycloserine, it can increase adverse reactions of the central nervous system (such as dizziness or drowsiness). The dose needs to be adjusted and the signs of central nervous system toxicity need to be closely observed, especially for patients who are engaged in work that requires high sensitivity. 17 This product can inhibit the metabolism of carbamazepine, increase its blood concentration, and cause toxic reactions; carbamazepine can induce the microsomal metabolism of isoniazid, increasing the amount of hepatotoxic intermediate metabolites. 18 When used in combination with acetaminophen, because isoniazid can induce liver cytochrome P450, the amount of toxic metabolites formed by the former increases, which can increase liver toxicity and kidney toxicity. 19 When used in combination with alfentanil, isoniazid can prolong the effect of alfentanil because it is a liver drug enzyme inhibitor; when used in combination with disulfiram, it can enhance its central nervous system effects, causing dizziness, incoordination, irritability, insomnia, etc.; when used in combination with enflurane, it can increase the formation of inorganic fluorine metabolites with nephrotoxicity. 20 Do not take it at the same time with ephedrine or belladonna to avoid or increase adverse reactions. 21 Aluminum-containing antacids can delay and reduce the absorption of isoniazid after oral administration, reducing blood drug concentrations. Avoid using it at the same time, or take this product at least 1 hour before oral antacids.

Sealed, store in a dark and dry place.

Each tablet contains 150 mg of rifampicin and 100 mg of isoniazid

Zhejiang Huisong Pharmaceuticals Co., Ltd.

• Founded in:

  1998-12-02

• Address:

  No. 39, 25th Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province

• Tax NO.:

  91330101710957739G

• Registered Funds:

  100.1 million yuan

• Website:

  Log in to view

• Email:

  Log in to view